JANKI PATEL to Middle Aged
This is a "connection" page, showing publications JANKI PATEL has written about Middle Aged.
Connection Strength
0.015
-
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 2025 Jan; 26(1):110-122.
Score: 0.015